Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Fournier, Montreal
Alyson Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20090221479 | Lgi, lingo and p75ntr family members: novel modulators of neuronal growth - The present invention relates to a novel method to promote regeneration or repair of the central or peripheral nervous system following injury The present invention concerns the use of a leucine-rich, glioma-inactivated protein (LGIn), or an analog or derivative thereof, to promote the regeneration or remyelination of neurons after injury to the central nervous system LGIns are endogenous proteins secreted by central neurons that promote regeneration of neurons after injury to the central nervous system The present invention includes an assay to measure the interaction of LGIn with LINGOn and p75NTRn as well as to identify factors that enhance or disrupt these interactions The invention further includes cell lines capable of expressing LGIn, LINGOn and p75NTRn molecules, as well as the proteins purified from these cells. | 09-03-2009 |
Alyson E. Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20090048169 | Identification of Crmp4 as a Convergent Regulator of Axon Outgrowth Inhibition - The present invention relates to the identification of the cytosolic phosphoprotein CRMP4b as a protein that physically and functionally interacts with RhoA to mediate neurite outgrowth inhibition. siRNA-mediated knockdown of CRMP4 promotes neurite outgrowth on myelin substrates indicating a critical role for CRMP4 in neurite outgrowth inhibition. Disruption of CRMP4b-RhoA binding with a competitive inhibitor attenuates neurite outgrowth inhibition on myelin and aggrecan substrates. Stimulation of neuronal growth cones with Nogo leads to co-localization of CRMP4b and RhoA at discrete regions within the actin-rich central and peripheral domains of the growth cone indicative of a potential function in cytoskeletal rearrangements during neurite outgrowth inhibition. Together these data indicate that a RhoA-CRMP4b complex forms in response to inhibitory challenges in the growth cone environment and regulate cytoskeletal dynamics at distinct sites necessary for axon outgrowth inhibition. Competitive inhibition of CRMP4b-RhoA binding suggests a novel, highly specific therapeutic avenue for promoting regeneration following CNS injury. | 02-19-2009 |
Charles-Olivier Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20080249194 | STABLE EMULSION AND PROCESS OF PREPARATION THEREOF - This document relates to a stable emulsion comprising a continuous phase and a dispersed phase comprising droplets. The droplets are at least partially covered with a powder and the powder comprises particles having an average size which is at least 10 times smaller than the average size of the droplets. A process for preparing the emulsion is also presented. | 10-09-2008 |
| 20080302672 | SYSTEMS AND METHODS FOR SENSING - A sensor system for measuring a plurality of chemical species is disclosed. The sensor system includes a plurality of semiconductor device sensor elements, wherein each sensor element includes at least one wide band gap semiconductor layer and at least one catalytic layer configured to have an electrical property modifiable on exposure to an analyte including one or more chemical species; and an acquisition and analysis system configured to receive sensor signals from the plurality of sensor elements and to use multivariate analysis techniques to analyze the sensor signals to provide multivariate analyte measurement data. | 12-11-2008 |
Daniel Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20090177420 | Detection, localization and interpretation of partial discharge - In order to detect, localize and interpret a partial discharge occurring in a partial discharge site along an electrical equipment, two measurement probes and a synchronization probe are installed along the electrical equipment. The measurement probes detect pulses travelling in the electrical equipment while the synchronization probe detects a phase angle in the electrical equipment and is usable for calibration purposes. A control unit receives the signals sensed by the probes and conditions them. Digital processings applied on the conditioned signals, involving their correlation, a time-frequency distribution and a form factor estimation, allows establishing a diagnosis indicating a detection of a partial discharge and its localization along the electrical equipment. | 07-09-2009 |
Helene Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20090081658 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 03-26-2009 |
| 20100081129 | Genemap of the human genes associated with crohn's disease - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-01-2010 |
| 20100144538 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH SCHIZOPHRENIA - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to SCHIZOPHRENIA disease and/or their response to a particular drug or drugs. | 06-10-2010 |
| 20100167285 | METHODS AND AGENTS FOR EVALUATING INFLAMMATORY BOWEL DISEASE, AND TARGETS FOR TREATMENT - The invention provides methods for evaluating irritable bowel disease (IBD), including Crohn Disease and Ulcerative Colitis, methods for determining a patient's susceptibility to developing an IBD, and methods for determining a patient's IBD genotype. The invention includes methods, polynucleotides, polypeptides, and antibodies relating to disclosed variants of, and polymorphisms in, the nel-like 1 precursor (NELL1), as well as the 5p13.1 locus, and other genes disclosed herein to be associated with IBD. Thus, the invention provides diagnostic and/or therapeutic targets for IBD, as well as diagnostic and therapeutic agents for IBD. | 07-01-2010 |
Hélene Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20100081129 | Genemap of the human genes associated with crohn's disease - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-01-2010 |
Jean-Francois Fournier, Montreal CA
| Patent application number | Description | Published |
|---|---|---|
| 20100298347 | SUBSTITUTED 2-NAPHTHOIC ACIDS AS ANTAGONISTS OF GPR105 ACTIVITY - Substituted 2-naphthoic acids of structural formula are effective as antagonists of the biological activity of GPR105 protein. They are useful for the treatment, control or prevention of disorders responsive to antagonism of this receptor, such as diabetes, particularly, Type 2 diabetes, insulin resistance, hyperglycemia, lipid disorders, obesity, atherosclerosis, and conditions associated with the Metabolic Syndrome. | 11-25-2010 |